Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET

Rhea-AI Summary

Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2022 financial results webcast on November 7, 2022 at 4:30 p.m. ET. The management, led by CEO Panna Sharma, will discuss the operating and financial results from the third quarter ended September 30, 2022, alongside future milestones. Lantern Pharma focuses on oncology drug discovery using its proprietary RADR® A.I. platform to identify patient populations likely to benefit from its drug candidates, including four candidates and an ADC program across nine tumor targets.

Positive

• Lantern Pharma is developing four drug candidates and an ADC program targeting nine tumor types.
• Utilizes the RADR® A.I. platform for better drug development efficiency.

Negative

• None

• Webcast to be held Monday Nov. 7, 4:30 p.m. ET, register here.

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its third quarter 2022 financial results webcast on Monday, November 7, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Management intends to discuss the operating and financial results for the third quarter ended September 30, 2022 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.

To register for the webinar, sign up here: https://us06web.zoom.us/webinar/register/3516649838262/WN_xlduE8e8Q_Wm_KgnTUDYVg

A replay of the webinar will be available after the call on the investor relations section of the Company's website at ir.lanternpharma.com.

About Lantern Pharma:

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across nine disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's drug development approach represents the potential to deliver best-in-class outcomes. Lantern is also partnering with leading academic institutions including Johns Hopkins, Fox Chase Cancer Center, and UT Health Science Center – San Antonio to accelerate the development of Lantern’s drug programs.

Please find more information at:

Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR^® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR^® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," “model,” "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR^® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005162/en/

Nicole Leber

Investor Relations Associate

ir@lanternpharma.com

Source: Lantern Pharma Inc.

FAQ

When will Lantern Pharma announce its Q3 2022 results?

Lantern Pharma will announce its Q3 2022 results on November 7, 2022, at 4:30 p.m. ET.

What is the focus of Lantern Pharma's drug development?

Lantern Pharma focuses on oncology drug discovery using its RADR® A.I. platform to target patients likely to respond positively to its therapies.

How many drug candidates is Lantern Pharma currently developing?

Lantern Pharma is currently developing four drug candidates and an antibody-drug conjugate (ADC) program.

What is the significance of the RADR® A.I. platform?

The RADR® A.I. platform is designed to enhance oncology drug discovery by identifying biomarker signatures and optimizing drug development timelines.